 |
|
|
| |
Dose Selection of Ultra-Long-Acting Cabotegravir as HIV-1 Pre-Exposure Prophylaxis: A Phase 1 Study
|
| |
| |
CROI 2026 Feb 22-25 Denver
Eileen Castronova,1 Jörg Sievers,2 Gilda Bontempo,3 Randa Hareedy,4 David Dorey,5 Lisa Morgan,1 Darin Brimhall,6 Brian Spears,7 Jon Collins,8 Susan L. Ford,9 Carolina Acuipil,8 Alex R. Rinehart,8 Lionel Tan,2 Ronald D’Amico8
1GSK, Collegeville, PA, USA; 2ViiV Healthcare, London, UK; 3ViiV Healthcare, Branford, CT, USA; 4GSK, London, UK; 5GSK, Mississauga, ON, Canada; 6PPD-Thermo Fisher Scientific, Las Vegas, NV, USA; 7PPD-Thermo Fisher Scientific, Austin, TX, USA; 8ViiV Healthcare, Durham, NC, USA; 9GSK, Durham, NC, USA
|
| |
|
|
|
|
|
